

1. Record Nr.	UNINA9910781802303321
Autore	Neidle Stephen
Titolo	Cancer drug design and discovery // Stephen Neidle
Pubbl/distr/stampa	London, : Academic, c2008
ISBN	1-281-76368-3 9786611763688 0-08-055495-4
Descrizione fisica	1 online resource (517 pages)
Disciplina	616.994061
Soggetti	Antineoplastic agents - Development Antineoplastic agents - Design
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Front Cover; Cancer Drug Design and Discovery; Copyright Page; Contents; About the editor; Contributors; Introduction; PART I: BASIC PRINCIPLES; Chapter 1 Modern cancer drug discovery: integrating targets, technologies and treatments; 1.1 Introduction: changing times; 1.2 Successes and limitations; 1.3 Integrated small-molecule drug discovery and development; 1.4 New molecular targets: the "druggable" cancer genome; 1.5 From drug target to development candidate; 1.6 Examples of case histories for molecularly targeted cancer therapeutics 1.7 Biomarkers, the pharmacological audit trail and clinical development; 1.8 Conclusions and outlook: towards individualized molecular cancer medicine; References; Chapter 2 Preclinical pharmacology and in vivo models; 2.1 Introduction; 2.2 Contemporary preclinical cancer drug discovery; 2.3 In vitro pharmacological evaluation; 2.4 Information gained from in vitro cell lines; 2.5 In vivo pharmacokinetics (PK) and pharmacodynamics (PD): continuing the pharmacological audit trail; 2.6 In vivo anti-tumor models: choice and predictiveness?; 2.7 Concluding remarks; References Chapter 3 Clinical trial designs for more rapid proof-of-principle and approval; 3.1 Introduction; 3.2 NDA plan at the time of IND; 3.3 Phase I trial design innovations; 3.4 Concept of a continuous Phase I; 3.5 Phase

II trial design innovations; 3.6 Phase III trial design innovations (enrichment designs); 3.7 Other approaches to enrich trial populations; 3.8 Innovations in design and selection of endpoints; 3.9 Regulatory strategies; 3.10 Other approaches to accelerate drug development; 3.11 New perspectives; 3.12 Summary; References; PART II:

METHODOLOGY

Chapter 4 Structural biology and anticancer drug design; 4.1 Introduction; 4.2 High-throughput X-ray crystallography; 4.3 Structural biology and structure-based drug design; 4.4 Fragment screening using X-ray crystallography; 4.5 Case history: cyclin-dependent kinase inhibitors, from fragment hit to clinical candidate; 4.6 Compound profiling; 4.7 Conclusions; References; Chapter 5 Natural product chemistry and anticancer drug discovery; 5.1 Introduction; 5.2 Exemestane (aromasin); 5.3 Fulvestrant/faslodex; 5.4 Flavonoids; 5.5 Bexarotene (targretin); 5.6 Epothilones; 5.7 Maytansine; 5.8 Geldanamycin; 5.9 UCN-01; 5.10 Camptothecin; 5.11 Prodigiosin; 5.12 Azacitidine; 5.13 FK-288; 5.14 Hemiasterlin; 5.15 Calicheamicin; 5.16 Conclusion; References; Chapter 6 Pharmacokinetics and ADME optimization in drug discovery; 6.1 Introduction; 6.2 Absorption; 6.3 Distribution; 6.4 Metabolism; 6.5 Elimination; 6.6 Biochemical barriers to drug therapy: efflux transporters; 6.7 Induction; 6.8 Conclusions; References; PART III: DRUGS IN THE CLINIC; Chapter 7 Temozolomide: from cytotoxic to molecularly-targeted agent; 7.1 Introduction; 7.2 Towards imidazotetrazines and azolastone (mitozolomide)

Sommario/riassunto

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design.